ClinicalTrials.gg
RecruitingNCT07358078DemonsTTRateUpdated Nov 19, 2026

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

An observational study in Transthyretin Amyloidosis With Cardiomyopathy, sponsored by Alnylam Pharmaceuticals. Recruiting at 29 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Alnylam Pharmaceuticals · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 19, 20265 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Amyloidosis by Alnylam Pharmaceuticals — 6 open to participants now, 7 under way, 4 of them phase 3. Amyloidosis · Alnylam Pharmaceuticals.

Started
2026
with 1 other
Observational
5 of 22
3 open now
Registered
22nd of 22
by date

Among the 22 studies in Amyloidosis by Alnylam Pharmaceuticals, this one is one of 2 that started in 2026, is one of 5 observational ones, and was the 22nd registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

6 of the 22 studies in Amyloidosis by Alnylam Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Amyloidosis by Alnylam Pharmaceuticals, or all of them as a file.
02

Study summary

The purpose of this study is to:

  • Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care
  • Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care
  • Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care
  • Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care
  • Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care
Read the detailed description

Each site will invite all eligible patients to participate. Patients will be followed for up to 5 years or until patient withdrawal of consent, loss to follow-up, death, or the end of the study, whichever comes first.

03

Conditions studied

  • Transthyretin Amyloidosis With Cardiomyopathy

Keywords

  • ATTR-CM
  • Transthyretin
  • Amyloidosis
  • ATTR
  • Cardiomyopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include adult patients with ATTR-CM who, at enrollment, are either initiating treatment with vutrisiran or are initiating treatment with another approved ATTR-CM therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a diagnosis of ATTR-CM
  • Is initiating treatment with vutrisiran or another approved ATTR-CM therapy

Exclusion criteria

Exclusion Criteria:

  • Is enrolled in an interventional clinical trial
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with ATTR-CM

    Patients with ATTR-CM.

06

What researchers measure

Primary outcomes

  1. New York Heart Association (NYHA) Class

    The NYHA functional classification categorizes the severity of heart failure. Patients are classified in 1 of 4 categories based on their physical limitations, as follows: * Class I No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or shortness of breath. * Class II Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. * Class III Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. * Class IV Symptoms of heart failure at rest. Any physical activity causes further discomfort.

    Time frame: From time of ATTR-CM diagnosis up to 5 years

  2. Outpatient Diuretic Intensification

    The clinician-reported outcome of ODI, which measures any post-diagnosis initiation or increase in the dose of loop diuretics, may help identify patients with ATTR-CM who are at an increased risk for adverse outcomes. ODI, a marker to monitor disease progression and/or worsening heart failure, is associated with a higher risk of all-cause mortality, cardiovascular hospitalizations, and urgent heart failure visits. Clinicians monitor ODI to help manage patients with ATTR-CM.

    Time frame: From time of enrollment for up to 5 years

  3. Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Score

    Norfolk-QoL-DN: The Norfolk QOL-DN questionnaire is a standardized 35-item patient-reported outcomes measure that assesses 6 domains: physical function, large-fiber neuropathy, activities of daily living, symptoms, small-fiber neuropathy, and autonomic neuropathy. The total score ranges from -4 points (best possible quality of life) to 136 points (worst possible quality of life).

    Time frame: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years

  4. Kansas City Cardiomyopathy Questionnaire (KCCQ)

    The KCCQ is a 23-item self-administered questionnaire developed to independently measure the patient's perception of health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life within a 2-week recall period. The KCCQ quantifies 6 domains (symptoms, physical function, quality of life, social limitation, self-efficacy, and symptom stability) and 2 summary scores (clinical and overall summary \[OS\] scores).

    Time frame: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years

  5. Patient Global Impressions - Change (PGI-C)

    The PGI-C is a 7-point numerical rating scale where 1 indicates "very much improved" and 7 indicates "very much worse."

    Time frame: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years

  6. Patient Global Impressions - Severity (PGI-S);

    The PGI-S is a 7-point numerical rating scale where 1 indicates "very much improved" and 7 indicates "very much worse."

    Time frame: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years

  7. Treatment Satisfaction Questionnaire for Medication version 9 (TSQM-9)

    TSQM-9 is a 9-item general instrument that measures the major dimensions of satisfaction with a medication. The questionnaire consists of 3 domains: effectiveness, convenience and side effects. The scores of each domain range from 0 to 100 with higher scores representing higher satisfaction on that domain.

    Time frame: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years

07

Study locations

29 of 29 sites recruiting
  • Clinical Trial Site
    Tucson, Arizona 85711, United States
    Recruiting
  • Clinical Trial Site
    Beverly Hills, California 90211, United States
    Recruiting
  • Clinical Trial Site
    La Jolla, California 92037, United States
    Recruiting
  • Clinical Trial Site
    Naples, Florida 34102, United States
    Recruiting
  • Clinical Trial Site
    Honolulu, Hawaii 96813, United States
    Recruiting
  • Clinical Trial Site
    Kansas City, Kansas 66160, United States
    Recruiting
  • Clinical Trial Site
    Boston, Massachusetts 02215, United States
    Recruiting
  • Clinical Trial Site
    St Louis, Missouri 63110, United States
    Recruiting
  • Clinical Trial Site
    New Brunswick, New Jersey 08901, United States
    Recruiting
  • Clinical Trial Site
    Charlotte, North Carolina 28270, United States
    Recruiting
  • Clinical Trial Site
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Clinical Trial Site
    Memphis, Tennessee 38120, United States
    Recruiting
  • Clinical Trial Site
    Dallas, Texas 75390, United States
    Recruiting
  • Clinical Trial Site
    Düsseldorf, Germany
    Recruiting
  • Clinical Trial Site
    Erlangen, Germany
    Recruiting
  • Clinical Trial Site
    Heidelberg, Germany
    Recruiting
  • Clinical Trial Site
    Munich, Germany
    Recruiting
  • Clinical Trial Site
    Münster, Germany
    Recruiting
  • Clinical Trial Site
    Würzburg, Germany
    Recruiting
  • Clinical Trial Site
    Bunkyō City, Japan
    Recruiting
  • Clinical Trial Site
    Kumamoto, Japan
    Recruiting
  • Clinical Trial Site
    Kurume, Japan
    Recruiting
  • Clinical Trial Site
    Matsumoto, Japan
    Recruiting
  • Clinical Trial Site
    Sendai, Japan
    Recruiting
  • Clinical Trial Site
    Shinjuku, Japan
    Recruiting
  • Clinical Trial Site
    Suita, Japan
    Recruiting
  • Clinical Trial Site
    Tsukuba, Japan
    Recruiting
  • Clinical Trial Site
    Ube, Japan
    Recruiting
  • Clinical Trial Site
    Yufu, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2030, 57 months after the start.

Of 52 observational studies under Amyloidosis, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 183. This study's planned 57 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Jan 22, 2026
StartActual
Jan 9, 2026
Primary completionEst.
Oct 23, 2030
CompletionEst.
Oct 23, 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added
Show 5 added (3 Germany, 2 United States)
  • Clinical Trial Site · La Jolla, United States
  • Clinical Trial Site · Honolulu, United States
  • Clinical Trial Site · Würzburg, Germany
  • Clinical Trial Site · Düsseldorf, Germany
  • Clinical Trial Site · Erlangen, Germany
across 2 updates, Oct 9, 2026 – Nov 19, 2026
Show all 2 updates
  1. Nov 19, 2026
    2 sites added
    Show 2 added (2 Germany)
    • Clinical Trial Site · Düsseldorf, Germany
    • Clinical Trial Site · Erlangen, Germany
    + 1 other change: verification date
  2. Oct 9, 2026
    3 sites added
    Show 3 added (2 United States, 1 Germany)
    • Clinical Trial Site · La Jolla, United States
    • Clinical Trial Site · Honolulu, United States
    • Clinical Trial Site · Würzburg, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07358078
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Jan 9, 2026
Primary completion
Oct 23, 2030 (estimated)
Completion
Oct 23, 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-ALNYLAM
Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-256-9526
Medical Director
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion